Addressing the challenges of applying precision oncology
10.1038/s41698-017-0032-z · doi-reference
Challenges and solutions to system‐wide use of precision oncology as the standard of care paradigm
10.1017/pcm.2024.1 · doi-reference
Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology
10.1016/j.isci.2025.114082 · doi-reference
AI‐driven multi‐omics integration in precision oncology: bridging the data deluge to clinical decisions
10.1007/s10238-025-01965-9 · doi-reference
PTOLEMI: personalized cancer treatment through machine learning‐enabled image analysis of microfluidic assays
10.3390/diagnostics13193075 · doi-reference
Applications of organoids for cancer biology and precision medicine
10.1038/s43018-020-0102-y · doi-reference
Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring
10.1200/edbk-25-481114 · doi-reference
Liquid biopsy to detect minimal residual disease: methodology and impact
10.3390/cancers13215364 · doi-reference
Integrating cfDNA liquid biopsy and organoid‐based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer
10.1186/s12967-023-04675-6 · doi-reference
Liquid biopsy in cancer drug resistance: real‐time monitoring, mechanistic insights, and translational applications
10.3389/fimmu.2026.1795789 · doi-reference
Personalized cancer vaccines: bridging immune‐oncology and precision medicine for advanced therapeutics
10.1038/s41392-026-02769-3 · doi-reference
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
10.3389/fimmu.2023.1246682 · doi-reference
Antibody drug conjugates in breast cancer: spotlight on HER2
10.1097/ppo.0000000000000634 · doi-reference
Bystander effect in antibody‐drug conjugates: navigating the fine line in tumor heterogeneity
10.1016/j.critrevonc.2025.104979 · doi-reference
The evolving landscape of antibody–drug conjugates: in depth analysis of recent research progress
10.1021/acs.bioconjchem.3c00374 · doi-reference
Clinical evidence for efficacy of pembrolizumab in MSI‐H and TMB‐H advanced solid tumor: results from three cancer centers in China
10.1007/s00262-024-03660-2 · doi-reference
Tumor type agnostic therapy carrying BRAF mutation: case reports and review of literature
10.3390/ph14020159 · doi-reference
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
10.1016/j.esmoop.2021.100204 · doi-reference
Trop2‐targeted therapies in solid tumors: advances and future directions
10.7150/thno.98178 · doi-reference
Tissue‐agnostic cancer therapies: promise, reality, and the path forward
10.1038/s41467-025-60369-1 · doi-reference
Oncogenic driver mutations, treatment, and EGFR‐TKI resistance in a Caucasian population with non‐small cell lung cancer: survival in clinical practice
10.18632/oncotarget.20857 · doi-reference
Patient‐derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology
10.1038/s12276-024-01272-5 · doi-reference
A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response
10.12659/msm.949300 · doi-reference
The good, the bad, and the ugly: opportunities, challenges, and pitfalls in spatial proteomics modeling
10.1093/bib/bbag169 · doi-reference
Spatial transcriptomics, proteomics, and epigenomics as tools in tissue engineering and regenerative medicine
10.3390/bioengineering11121235 · doi-reference
Single‐cell multiomics
10.1146/annurev-biodatasci-020422-050645 · doi-reference
Significance and limitations of the use of next‐generation sequencing technologies for detecting mutational signatures
10.1016/j.dnarep.2021.103200 · doi-reference
Cancer‐associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications
10.1186/s12943-025-02533-1 · doi-reference
Spatial omics in clinical research: a comprehensive review of technologies and guidelines for applications
10.3390/ijms26093949 · doi-reference
From morphology to single‐cell molecules: high‐resolution 3D histology in biomedicine
10.1186/s12943-025-02240-x · doi-reference
Microfluidic single‐cell transcriptomics: moving towards multimodal and spatiotemporal omics
10.1039/d1lc00607j · doi-reference
The technological landscape and applications of single‐cell multi‐omics
10.1038/s41580-023-00615-w · doi-reference
Advances in microfluidic systems and numerical modeling in biomedical applications: a review
10.3390/mi15070873 · doi-reference
Quantitative analysis of IGF1R/AKT/mTOR pathway using multiplex immunoprecipitation and targeted mass spectrometry
10.1158/1538-7445.am2016-3884 · doi-reference
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
10.1186/s12943-023-01827-6 · doi-reference
Proteomic analysis of protein posttranslational modifications by mass spectrometry
10.1101/pdb.top077743 · doi-reference
RNA‐Seq: a revolutionary tool for transcriptomics
10.1038/nrg2484 · doi-reference
Advances in epigenomic sequencing and their applications in cancer diagnostics
10.1021/prechem.5c00014 · doi-reference
The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair
10.3390/cancers14122950 · doi-reference
Microsatellite instability: a review of molecular epidemiology and implications for immune checkpoint inhibitor therapy
10.3390/cancers15082288 · doi-reference
